You are here

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Last updated on March 22, 2018

FOR MORE INFORMATION
Study Location
Arcadia MRI & Imaging Center
Arcadia, California, 91007 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Schizophrenia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-45 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Subjects with schizophrenia both male and female

2. Evidence of stable schizophrenia symptomatology for at least 3 months (no
hospitalizations for schizophrenia, no increase in level of psychiatric care due to
worsening of symptoms of schizophrenia, etc).

3. Subjects must be in ongoing maintenance antipsychotic therapy other than clozapine
(oral or depot) on a stable medication treatment regimen for for at least 2 months
prior to Day 1, including concomitant psychotropic medications.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. History of seizure

2. Pregnant or nursing females

3. Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease
(including drug allergies, but excluding untreated, asymptomatic, seasonal allergies
at time of screening and at the time of dosing).

NCT02418819
Pfizer
Completed
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia
A Randomized, Double-blind, Placebo Controlled, Parallel Group, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06412562 In Psychiatrically Stable Subjects With Schizophrenia
This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in subjects with schizophrenia.

B7441007 is a randomized, double-blind, placebo-controlled, sponsor open, parallel group design, Phase 1b study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of 3 doses of PF-06412562 (3 mg BID, 9 mg BID and 45 mg BID) over 15 days in approximately 100 psychiatrically stable (as defined by the inclusion and exclusion criteria) subjects with schizophrenia are on background treatment with SOC antipsychotics and other psychotropic medications.

All doses will be administered twice daily, with approximately 12 hours between each dose.

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Schizophrenia
  • Drug: PF-06412562 3mg BID
    PF-06412562
    Other Name: PF-06412562 3mg
  • Drug: PF-06412562 9mg BID
    PF-06412562
    Other Name: PF-06412562 9mg
  • Drug: PF-06412562 45mg BID
    PF-06412562
    Other Name: PF-06412562 45mg
  • Other: Placebo
    Placebo
  • Experimental: PF-06412562 3mg
    PF-06412562 3mg BID
    Intervention: Drug: PF-06412562 3mg BID
  • Experimental: PF-06412562 9mg
    PF-06412562 9mg BID
    Intervention: Drug: PF-06412562 9mg BID
  • Experimental: PF-06412562 45mg
    PF-06412562 45mg BID
    Intervention: Drug: PF-06412562 45mg BID
  • Placebo Comparator: Placebo
    Placebo BID
    Intervention: Other: Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
October 2016
October 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subjects with schizophrenia both male and female
  2. Evidence of stable schizophrenia symptomatology for at least 3 months (no hospitalizations for schizophrenia, no increase in level of psychiatric care due to worsening of symptoms of schizophrenia, etc).
  3. Subjects must be in ongoing maintenance antipsychotic therapy other than clozapine (oral or depot) on a stable medication treatment regimen for for at least 2 months prior to Day 1, including concomitant psychotropic medications.

Exclusion Criteria:

  1. History of seizure
  2. Pregnant or nursing females
  3. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of screening and at the time of dosing).
Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02418819
B7441007
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2016

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now